Solcitinib

DB19856InvestigationalSmall molecule

Solcitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Solcitinib is a Janus kinase inhibitor. Solcitinib is under investigation in clinical... Solcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184).

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK1
Curator reviewed
Formula / weight: C₂₂H₂₃N₅O₂ · 389.459 g/mol (avg)
Code names: G-154578 · GLPG-0778 · GLPG-0788 · GSK-2586184 · GSK-2586184A

Resolves to

Compound

UNII3V7GQ1260KCAS1206163-45-2ChEMBLCHEMBL3301606ChEBI755289PubChem44603362

Structure

InChIKeyMPYACSQFXVMWNO-UHFFFAOYSA-NSMILESCC1(C)CN(C1)C(=O)C1=CC=C(C=C1)C1=CC=CC2=NC(NC(=O)C3CC3)=NN12

Targets

P23458JAK1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Solcitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account